Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.25.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
REVENUES:    
Product revenue, net $ 13,107 $ 10,094
COSTS AND EXPENSES:    
Cost of sales 6,640 7,765
Research and development 44,486 39,972
Selling, general and administrative 87,684 40,101
Asset impairment charges 58,957
 Total Operating Expenses 138,810 146,795
Operating loss (125,703) (136,701)
Grant income 3,012 2,594
Gain on change in fair value of warrant liabilities 6,150
Loss on extinguishment of debt (2,092) 0
Interest income 4,146 22
Interest expense (89) (1,234)
Other expense, net (3,295) (867)
Net loss available to common stockholders $ (124,021) $ (130,036)
Net loss to common stockholders per common share, basic $ (14.57) $ (176.60)
Net loss to common stockholders per common share, diluted $ (14.57) $ (176.60)
Weighted average common shares outstanding, basic 8,511,318 736,339
Weighted average common shares outstanding, diluted 8,511,318 736,339